The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. (Q51344608)

4 April 2018

title

The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. (English)

1 reference

4 April 2018

1 reference

Tung-Liang Lin

1

1 reference

4 April 2018

Ming-Chung Kuo

2

1 reference

4 April 2018

Lee-Yung Shih

3

1 reference

4 April 2018

Po Dunn

4

1 reference

4 April 2018

Po-Nan Wang

5

1 reference

4 April 2018

Jin-Hou Wu

6

1 reference

4 April 2018

Tzung-Chih Tang

7

1 reference

4 April 2018

Hung Chang

8

1 reference

4 April 2018

Yu-Shin Hung

9

1 reference

4 April 2018

publication date

18 April 2012

1 reference

4 April 2018

published in

Annals of Hematology

1 reference

4 April 2018

volume

91

1 reference

4 April 2018

issue

9

1 reference

4 April 2018

page(s)

1383-1391

1 reference

4 April 2018

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

Validation of the Charlson comorbidity index in patients with head and neck cancer: a multi-institutional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

Evaluation of Charlson-Age Comorbidity Index as predictor of morbidity and mortality in patients with colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

Prediction of mortality after radical prostatectomy by Charlson comorbidity index

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma - a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

How I treat elderly patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

Predictive ability of Charlson comorbidity index on outcomes from lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-012-1463-9

10.1007/S00277-012-1463-9

21 January 2018

Identifiers

DOI

1 reference

4 April 2018

1 reference

4 April 2018